新诊断多发性骨髓瘤患者中1p32.3缺失在单一单等位缺失和/或主克隆中预后不良
该研究分析345例新诊断多发性骨髓瘤(NDMM)样本,采用Cytoscan和FISH检测细胞遗传学,发现1p32.3缺失与1q21获得/扩增及17p缺失强相关,且伴髓外病变和复杂核型。1p32.3缺失对无进展生存(PFS)和总生存(OS)有更差影响,主克隆或单一单等位缺失者生存显著更差,自体干细胞移植(ASCT)不能完全克服其不良预后。
要点
- 1p32.3缺失患者更常伴1q21获得/扩增、17p缺失、髓外病变和复杂核型。
- 1p32.3缺失对PFS和OS有更差影响,主克隆或单一单等位缺失者生存显著更差。
- ASCT不能完全克服1p32.3缺失的不良预后影响。
核心结论
- 1p32.3缺失是新诊断多发性骨髓瘤的重要独立不良PFS因素,主克隆或单一单等位缺失者预后更差。
- 1p32.3缺失与1q21获得/扩增常协同出现,作者强烈倡导临床常规检测del(1p32.3)。
研究设计与样本
- 研究分析了345例新诊断多发性骨髓瘤(NDMM)样本,采用Cytoscan和FISH进行细胞遗传学分析。
- 研究进行疾病特异性队列分析和预后模型构建。
主要发现
- 染色体1异常总比例为64.1%,包括189例1q21获得/扩增和88例1p缺失,40例患者有1p32.3/CDKN2C缺失。
- Del(1p32.3)患者与1q21获得/扩增和17p缺失强相关,更常伴髓外多发性骨髓瘤(EMM)和复杂核型。
- Del(1p32.3)对无进展生存(PFS)和总生存(OS)有更差影响,合并其他高危细胞遗传学异常进一步恶化预后,尤其是1q获得/扩增。
- 主克隆或单一单等位1p32.3缺失患者生存结局显著更差。
- 多因素分析中,1p32.3是重要的独立不良PFS因素。
关键数值与推荐
- 染色体1异常总比例为64.1%,包括189例1q21获得/扩增和88例1p缺失,40例患者有1p32.3/CDKN2C缺失。
临床怎么用
- 作者强烈倡导在临床实践中常规检测del(1p32.3)。
- 携带单一单等位del(1p32.3)和/或主克隆缺失的患者,尽管接受来那度胺、硼替佐米和地塞米松(VRD)诱导及移植,仍显示较差结局。
- 自体干细胞移植(ASCT)不能完全克服1p32.3缺失对预后的不良影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Del(1p32.3) by FISH detection in multiple myeloma (MM) has not been routinely carried out in China. Its clinical significance was not clearly demonstrated. This study analysed clinical characteristics, treatment response and prognostic significance of del(1p32.3). We analysed 345 newly diagnosed multiple myeloma (NDMM) samples, and cytogenetic analysis was performed using Cytoscan and FISH results, enabling comprehensive disease-specific cohort analysis and prognostic model development. The total proportion of chromosomal 1 abnormality was 64.1%, including 189 cases of 1q21 gain/amplification and 88 cases of 1p deletion, 40 patients had 1p32.3/CDKN2Cdeletion. Del(1p32.3) patients were strongly correlated with 1q21 gain/amplification and 17p deletion. Del(1p32.3) patients were more likely accompanied with extra-medullary multiple myeloma (EMM) and complex karyotype. Del(1p32.3) had a worse effect on progression-free survival (PFS) and overall survival (OS), alongside other high-risk cytogenetic abnormalities that further worsened prognosis, especially 1q gain/amplification. Patients with 1p32.3 in the main clone or with a single monoallelic deletion had significantly poorer survival outcomes. Autologous stem cell transplantation (ASCT) cannot completely overcome its adverse effects on prognosis. In multivariate analysis, 1p32.3 was an important independent adverse PFS factor. Patients harbouring single monoallelic del(1p32.3) and/or main clone deletions demonstrated inferior outcomes despite lenalidomide, bortezomib and dexamethasone (VRD) induction and transplantation. Del(1p32.3) had synergistic effects frequently co-occurring with 1q21 gain/amplification, thus, we strongly advocate for routine del(1p32.3) testing in clinical practice.
引用
- You H, Yao W, Yan L, et al. Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone. Br J Haematol. 2025. PMID: 40824203. doi:10.1111/bjh.70015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。